[The clinical observation of different therapeutic strategies in combined primary biliary cirrhosis and Sjögren syndrome]

Zhonghua Nei Ke Za Zhi. 2012 Nov;51(11):851-4.
[Article in Chinese]

Abstract

Objective: To investigate the role of different therapeutic regimens in primary biliary cirrhosis (PBC)complicating Sjögren syndrome (SS).

Methods: A total of 79 patients diagnosed as PBC complicating SS were enrolled and randomly divided into three groups: Group U (29 patients) received ursodeoxycholic acid (UDCA) alone, Group UP (37 patients) received UDCA and prednisolone, Group UA (13 patients) received UDCA and azathioprine. The clinical and laboratory data were collected at 0, 3, 6 and 12 months after treatment.

Results: Fatigue and pruritus were improved in each group with no difference among them (P > 0.05). The levels of ALT, AST, alkaline phophatase (ALP), gamma-glutamyl transferase (GGT), TBil, DBil, IgG, and IgM in the three groups were all decreased after treatment (P < 0.05), while there were no statistical differences among the three groups (P > 0.05).

Conclusions: The combination therapy of UDCA with prednisolone or azathioprine was not better than UDCA alone. The therapeutic policy of PBC complicating SS involved in the liver should settle PBC mainly.

Publication types

  • English Abstract
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Azathioprine / administration & dosage
  • Azathioprine / therapeutic use*
  • Female
  • Humans
  • Liver Cirrhosis, Biliary / complications
  • Liver Cirrhosis, Biliary / drug therapy*
  • Male
  • Middle Aged
  • Prednisolone / administration & dosage
  • Prednisolone / therapeutic use*
  • Sjogren's Syndrome / complications
  • Sjogren's Syndrome / drug therapy*
  • Treatment Outcome
  • Ursodeoxycholic Acid / administration & dosage
  • Ursodeoxycholic Acid / therapeutic use*

Substances

  • Ursodeoxycholic Acid
  • Prednisolone
  • Azathioprine